Trials
3 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Teverelix DP 540 mg Day 1 and 360 mg every 6 weeks from week 4 to week 16.”In the company’s words, NCT07457164 on ClinicalTrials.gov
- Tested for
- Advanced Prostate Cancer, GnRH Antagonist, Acute Urinary Retention, Benign Prostate Hypertrophy(BPH), Endometriosis Pelvic, Endometriosis Ovaries, Premenopausal, Endometriosis (Diagnosis) and 2 more
- Main trialPhase 2
- “The purpose of this clinical trial is to test the effectiveness of a dosing regimen of Teverelix DP castration rate defined as the cumulative probability of testosterone suppression to \< 0.5 ng/mL with the lower bound of the 95% confidence interval (CI) being \> 90% to meet the evaluation criteria for efficacy. The main question it aims to answer is: •Is the dosing regimen of Teverelix DP in this study effective at achieving the required testosterone suppression to castrate levels. Participants will * Receive a single loading dose consisting of 3 injections of teverelix DP (180 mg IM +…”In the company’s words, NCT07457164 on ClinicalTrials.gov
Other drugs for Advanced Prostate Cancer
- ApalutamideJohnson & Johnson (Janssen) · Phase 3
- 64Cu-SAR-bisPSMAClarity Pharmaceuticals Ltd · Phase 3
- Abiraterone acetateJohnson & Johnson (Janssen) · Phase 3
- 68Ga-PSMA-11Telix Pharmaceuticals (Innovations) Pty Limited · Phase 3
- EnzalutamidePfizer · Astellas · Phase 3
- MevrometostatPfizer · Phase 3
Coming up3
- Sep 2027Phase 2 trial completes · ClinicalTrials.gov
- May 2028Phase 2 trial completes · ClinicalTrials.gov
- Dec 2029Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Sep 2027 | A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer | |
| Phase 2Not yet recruiting | May 2028 | Study of Teverelix DP on Prostate Volume, Urinary Function and Clinical Outcomes Following Acute Urinary Retention | |
| Phase 2Not yet recruiting | Dec 2029 | PRECISION-E2: Teverelix in Women With Endometriosis - Pharmacodynamics, Safety and Precision Medicine Correlates |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026